Calcitonin/CALCA Protein, Human (HEK293, Fc)

Calcitonin/CALCA Protein (Human), a member of calcitonin-like protein family, is a peptide hormone secreted by parafollicular cells (C cells) of the thyroid (endostyle). Calcitonin/CALCA Protein (Human) reduces blood calcium Ca²⁺ and inhibits the effects of parathyroid hormone (PTH), which is used an antagonist against PTH and Vitamin D3a. Calcitonin/CALCA Protein (Human) has been used widely for research of bone disorders such as osteoporosis, hypercalcemia, and Paget’s disease. Calcitonin/CALCA Protein, Human (HEK293, Fc) is a recombinant protein with a Fc label that consists of 141amino acids and is expressed in HEK293^{[1][2][3][4][5]}.

Calcitonin, encoded by the CALCA gene, induces a rapid yet transient reduction in blood calcium and phosphate levels by facilitating the incorporation of these ions into bones. This hormone plays a crucial role in calcium homeostasis, functioning as a counter-regulatory mechanism to maintain balanced mineral levels in the bloodstream. Additionally, katacalcin, a peptide derived from the CALCA gene, is identified as a potent plasma calcium-lowering factor. The ability of calcitonin to modulate bone resorption and regulate circulating mineral concentrations underscores its significance in skeletal health and systemic mineral balance. Further exploration of the molecular pathways involved in these actions may contribute to a deeper understanding of calcitonin's role and potential therapeutic applications in conditions related to abnormal calcium metabolism^[1].
Calcitonin/CALCA Protein (Human) lowers blood Ca²⁺ levels by inhibiting osteoclast activity in bones and Inhibiting renal tubular cell reabsorption of Ca²⁺ and phosphate leading to marked hypocalcemia^[3].
Calcitonin/CALCA Protein (Human) protects against calcium loss from the skeleton by the direct inhibition of bone resorption and the indirect effect through the inhibition of the release of prolactin from the pituitary gland during periods of calcium mobilization in skeleton-preserving actions^[6,7].
Calcitonin/CALCA Protein (Human) lowers blood calcium and phosphorus mainly through its inhibition of osteoclasts and prevents postprandial hypercalcemia resulting from absorption of Ca^2+[8].

Calcitonin/CALCA Protein (Human) (10 nM, 8 days) inhibits the PTH-stimulated calcium release and basal ⁴⁵Ca-release from the bone^[3].
Calcitonin/CALCA Protein (Human) (0.01-10000 nM, 48 h) inhibits PTH (10 nM)-stimulated bone resorption in a dose-dependent manner^[5].

The serum Calcitonin/CALCA Protein (Human) levels are significantly greater in thyroid intact (CT+) rats than thyroidectomized (CT-) controls during parathyroid hormone (PTH)-induced hypercalcemia^[4].

Human

HEK293

C-hFc

P01258-1 (A26-N141)

796  [NCBI]

Full Length of Mature Protein

APFRSALESSPADPATLSEDEARLLLAALVQDYVQMKASELEQEQEREGSSLDSPRSKRCGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAPGKKRDMSSDLERDHRPHVSMPQNAN

Approximately 40-48 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. /biology-dictionary/hepg2-cell.html  [Content Brief]

  [2]. Sekiguchi T, et al. Evidence for Conservation of the Calcitonin Superfamily and Activity-regulating Mechanisms in the Basal Chordate Branchiostoma floridae: INSIGHTS INTO THE MOLECULAR AND FUNCTIONAL EVOLUTION IN CHORDATES. J Biol Chem. 2016 Jan 29;291(5):2345-56.  [Content Brief]

  [3]. Xie J, et al. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations. Int J Endocrinol. 2020 Sep 10;2020:3236828.  [Content Brief]

  [4]. Carney SL. Calcitonin and human renal calcium and electrolyte transport. Miner Electrolyte Metab. 1997;23(1):43-7.  [Content Brief]

  [5]. Rodriguez M, et al. Calcitonin, an important factor in the calcemic response to parathyroid hormone in the rat. Kidney Int. 1991 Aug;40(2):219-25.  [Content Brief]

  [6]. Yamamoto I, et al. Human calcitonin gene-related peptide possesses weak inhibitory potency of bone resorption in vitro. Calcif Tissue Int. 1986 Jun;38(6):339-41.  [Content Brief]

  [7]. Horwitz MJ,et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005 Oct;20(10):1792-803.  [Content Brief]

  [8]. Woodrow JP, et al. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology. 2006 Sep;147(9):4010-21.  [Content Brief]

  [9]. Inzerillo AM, et al. Calcitonin: physiological actions and clinical applications. J Pediatr Endocrinol Metab. 2004 Jul;17(7):931-40.  [Content Brief]